Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00498043 Completed - Lymphoma, B-Cell Clinical Trials

A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma

LNH2007-3B
Start date: July 2007
Phase: Phase 2
Study type: Interventional

This Phase II study randomized R-ACVBP and R-CHOP as induction treatment in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI. The consolidation treatment is allocated according to the response to induction treatment assessed by PET after the 2nd and 4th induction cycles.

NCT ID: NCT00496873 Completed - Lymphoma Clinical Trials

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or bulky lymphoma. The safety of this treatment will also be studied.

NCT ID: NCT00494780 Completed - Clinical trials for Lymphoma, Follicular

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

MUNIN
Start date: June 2007
Phase: Phase 2
Study type: Interventional

To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)

NCT ID: NCT00493467 Completed - Lymphoma Clinical Trials

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.

NCT ID: NCT00491491 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Zevalin-beam for Aggressive Lymphoma

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.

NCT ID: NCT00491127 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study it to evaluate efficacy of gemcitabine with cisplatin and dexamethasone in patients with aggressive non-Hodgkin's lymphoma who have previously progressed on first line of chemotherapy with anthracyclines.

NCT ID: NCT00490529 Completed - Clinical trials for Lymphoma, Mantle-Cell

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.

NCT ID: NCT00490009 Completed - Lymphoma Clinical Trials

Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma

Start date: September 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to obtain safety and efficacy data using tositumomab or Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).

NCT ID: NCT00489203 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Start date: April 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer.

NCT ID: NCT00487513 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

Start date: June 2007
Phase: N/A
Study type: Observational

In order to learn more about follicular lymphoma and anti-cancer vaccines, we are collecting samples from people with this diagnosis. We then hope to make a vaccine from this tissue to help the immune system destroy cancer cells. We plan on keeping samples in the tissue bank indefinitely.